Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300· Phase 3· Eli Lilly and Company· Source
Contact: Huang-Li Lin (principal investigator)
Recruiting
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336· Phase 3· Eli Lilly and Company· Source
Contact: Fu-Sung Lo (principal investigator)
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595· Phase 2· Eli Lilly and Company· Source
Contact: WEI-MIN HO (principal investigator)
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· Phase 3· Bristol-Myers Squibb· Source
Contact: Cheng-Ta Yang, Site 0388
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694· Phase 2/3· Pfizer· Source
Recruiting
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507· Phase 2· Eli Lilly and Company· Source
Contact: Huang-Li Lin (principal investigator)
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011· Phase 3· Eli Lilly and Company· Source
Contact: Hsueh-Yu Li (principal investigator)
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190· Phase 3· Eli Lilly and Company· Source
Contact: Chia-Hung Lin (principal investigator)
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756· Phase 3· Eli Lilly and Company· Source
Contact: Huang-Li Lin (principal investigator)
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Chen-Yang Huang, Site 0112
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Hung-Chih Hsu, Site 0449
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Eli Lilly and Company· Source
Contact: Yung-Chang Lin (principal investigator)
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600· Phase 3· Eli Lilly and Company· Source
Contact: Chia-Hung Lin (principal investigator)
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Eli Lilly and Company· Source
Contact: See-Tong Pang (principal investigator)
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· Phase 3· Pfizer· Source
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453· Phase 3· Bristol-Myers Squibb· Source
Contact: Yu-Huei Huang, Site 0112
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· Phase 3· Eli Lilly and Company· Source
Contact: Pao-Hsien Chu (principal investigator)
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593· Phase 3· Eli Lilly and Company· Source
Contact: Pao-Hsien Chu (principal investigator)
Active, not recruiting
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· Phase 3· Eli Lilly and Company· Source
Contact: WEI CHUN CHEN (principal investigator)
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953· Phase 3· Eli Lilly and Company· Source
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Contact: Chao Wei Hsu (principal investigator)
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732· Phase 3· Bristol-Myers Squibb· Source
Contact: Yi-chun Chen, Site 1752
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581· Phase 2· Pfizer· Source
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945· Phase 3· Pfizer· Source
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· Phase 3· Eli Lilly and Company· Source
Contact: Cheng-Ta Yang (principal investigator)
Active, not recruiting
A Phase 3 Study of NTLA-2001 in ATTRv-PN
NCT06672237· Phase 3· Intellia Therapeutics· Source
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324· Phase 3· Pfizer· Source
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632· Phase 2· Pfizer· Source
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Contact: Cheng-Ta Yang (principal investigator)
Active, not recruiting
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183· Phase 3· Pfizer· Source
Recruiting
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786· Phase 3· Pfizer· Source
Enrolling by invitation
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05735483· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623· Phase 3· Pfizer· Source
Recruiting
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198· Phase 3· Eli Lilly and Company· Source
Contact: Wen-Hung Chung (principal investigator)
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416· Phase 3· Pfizer· Source
Active, not recruiting
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
NCT05169567· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
NCT05059522· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421· Phase 3· Pfizer· Source
Active, not recruiting
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797· Phase 1/2· Eisai Inc.· Source
Showing 50 of 52.